Name Eligible Study sites More information
Abatacept (Orencia) Active DM/PM/NM/JDM (over 18), overlap 78 sites in US, Australia, S. America, Asia, Europe More details; BMS StudyConnect; NCT02971683
Abatacept for treatment of myositis-associated interstitial lung disease (Attack My-ILD) ILD + antisynthetase antibody (Jo-1, PL-7, PL-12, EJ, OJ, KS) Los Angeles, CA, Denver, CO, Baltimore, MD, Boston, MA, Pittsburgh, PA More details; Courtney Ward 412-648-9989; NCT03215927
Arimoclomol sIBM Kansas City, MO, London, UK +9 other sites expected More details; Laura Herbelin 913-588-5095; NCT02753530
Belimumab Active DM/PM Sites in Long Island, NY, Phoenix, AZ, and UC Irvine, CA More details; Preeya Nandkumar; NCT02347891
KZR-616 Active DM, PM 10 sites in US More details; 650-822-5600; NCT04033926
IVIg (Octagam 10%) DM 27 sites worldwide More details; Mikaela Grupp 866-337-1868; NCT02728752
Lenabasum Adults with DM 12 sites in US, more expected More details; Lindsey Smith 1-617-963-0707; NCT03813160
PF-06823859 DM 12 sites in US More details; 1-800-718-1021; NCT03181893
Rituximab vs Cyclophospahamide in Connective Tissue Disease-ILD (RECITAL) DM, PM, MCTD + ILD London, UK More details; Toby M Maher 02073518018; NCT01862926
Sodium thiosulfate for treatment of calcinosis associated with juvenile and adult dermatomyositis DM and JDM with calcinosis National Institutes of Health, Bethesda, MD More details; Adam Schiffenbauer 301-451-6270; NCT03267277
IgPro20 (Hizentra) Active DM, ADM (over 18) 94 sites in US, Australia, Japan, Argentina, Mexico, Europe, Ukraine, Russia More details; Trial Registration Coordinator 610-878-4000; NCT04044690
Tofacitinib (Xeljanz) Adults w DM w active, treatment resistant disease Johns Hopkins More details; Julie Paik, MD 410-550-1741; NCT03002649